Specialty Pharmacy

Merck is seeking FDA approval for its once-daily, single-tablet grazoprevir/elbasvir combination for the treatment of adult patients with chronic hepatitis C virus (HCV) genotypes 1, 4, or 6 infection.

A pair of large RNA classes associated with a protein that may play a role in cancer progression.

Top stories of the week on Specialty Pharmacy Times from May 25 to May 29.

Uncertainty persists in how collagen influences cancer cell behavior.

Nearly 1 in 4 patients treated in childhood for Hodgkin's lymphoma developed a second type of cancer within 30 years.

Legislation has been introduced in Congress to rein in skyrocketing generic drug prices.

Treatment advances have caused significant progress in survivorship.

Monitors alert health workers when a vaccine has potentially been compromised by cold chain failures.

Treatment utilizes immune cells grown from patient bone marrow to treat multiple myeloma.

The FDA today approved sirolimus, the first drug to treat lymphangioleiomyomatosis, a rare lung disease.

Novel drug target found in cells directly responsible for cartilage damage in affected joints.

Treatment is the first concentrated mealtime insulin analog to be approved by the FDA.

Marc O'Connor, Chief Operating Officer of Curant Health, discusses potential methods for keeping high cost drugs accessible.

Amgen has terminated its co-development and commercialization of brodalumab with AstraZeneca after observing suicidal ideation and behavior in clinical trial participants.

Genetic variant found to be associated with the likelihood of patient response to interferon-beta.

Smokers face high risk of disease recurrence after completing treatment.

Discovery may accelerate search for effective vaccine.

The FDA today approved a new treatment for chronic obstructive pulmonary disease: tiotropium bromide and olodaterol inhalation spray.

Electronic prescribing technology is permitting pharmacists to focus less on administrative tasks and more on providing direct patient care.

Investigational drug will move to phase 3 studies.

No significant differences in use found between opioid users and nonusers.

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the partnership between the National Association for Specialty Pharmacy and Specialty Pharmacy Times.

Treatment prior to surgery leads to fewer side effects and better quality of life.

Top stories of the week on Specialty Pharmacy Times from May 18 to May 22.

Persistent HIV reservoirs present ongoing treatment challenge.

Acute lymphoblastic leukemia accounts for nearly 25% of cancer diagnoses in children under 15 years of age.

Drug mitigates elevated cardiovascular risk in infected patients.

Genetic variant regulates response to leading multiple sclerosis therapy.